Diphereline 3.75mg is commonly prescribed by doctors for the treatment of prostate cancer, endometriosis, precocious puberty, female infertility,... During treatment with Diphereline 3.75mg, patients should adhere strictly to the medication regimen as prescribed by their doctor.
1. What is Diphereline 3 75mg?
Diphereline 3.75mg is an ETC drug used for the treatment of conditions such as prostate cancer, stage I-IV endometriosis, precocious puberty in both boys and girls, female infertility, or pre-surgical treatment for uterine fibroids. Currently, Diphereline 3.75mg is manufactured by Ipsen Pharma Biotech (France) and is available in the form of a powder for injectable suspension. Each box contains a vial of powder, a syringe, a 2ml solvent ampoule, and two injection needles.
Each vial of Diphereline 3.75mg contains the following components:
- Active ingredient: Triptorelin 3.75mg
- Excipients: Polysorbate 80, Mannitol, D,L lactide Coglycolide Polymer, Sodium Carmellose, Mannitol, and Water for Injection.
2. What is the effect of Diphereline 3.75mg?
2.1. Uses of Diphereline 3 75mg
The active ingredient Triptoreline in Diphereline 3.75mg acts as a synthetic decapeptide similar to natural GnRH. It has the ability to inhibit gonadotropic secretion, thereby causing a loss of function in the ovaries in women and the testes in men.
Studies have shown that Triptoreline directly affects the gonadal glands in the human body by reducing the sensitivity of peripheral GnRH receptors. Additionally, Triptoreline also helps in the development of fully mature ovarian follicles, which contributes to the effective treatment of female infertility.
2.2. Indications for the use of Diphereline 3.75mg
Diphereline 3.75mg is commonly prescribed by doctors for the treatment of the following conditions:
- Locally advanced or metastatic prostate cancer. The treatment efficacy of Diphereline 3.75mg is higher if the patient has never used any hormone therapy. It can be used as monotherapy or in combination with radiation therapy.
- For the treatment of precocious puberty in boys under 10 years old and girls under 8 years old.
- For the treatment of endometriosis in women at stages I-IV. Diphereline 3.75mg should not be used for longer than 6 months and should be administered only in a single course.
- Female infertility: Diphereline 3.75mg may be combined with gonadotropins (such as hCG, FSH, and hMG) to stimulate ovulation and facilitate embryo transfer (in vitro fertilization).
- Preoperative treatment for uterine fibroids: For patients with uterine fibroids associated with anemia (hemoglobin levels ≤ 8g/dl). Diphereline 3.75mg is prescribed to reduce the size of the fibroids, making laparoscopic or vaginal surgery easier and more effective. Treatment duration is generally limited to 3 months.
2.3. Contraindications for the use of Diphereline 3.75mg
Diphereline 3.75mg should not be used in the following cases without a doctor's prescription:
- The drug should not be used in patients who have shown hypersensitivity to the active ingredient Triptorelin, Dextran, Poly-(d, l lactide coglycolide), or any other excipients
- The drug should not be used in patients who have shown hypersensitivity to Gonadotropin-Releasing Hormone (GnRH) or any GnRH analogs
- Diphereline 3.75mg should not be used by pregnant women or women who are breastfeeding.
3. Dosage and Administration of Diphereline 3.75mg
3.1. Recommended Dosage of Diphereline 3.75mg
Below is the drug Diphereline 3 75mg according to the doctor's promotion for each specific patient group:
Dosage for Prostate Cancer Treatment:
Patients can choose one of the following two regimens:
- Subcutaneous injection of 1 dose of Diphereline 0,1mg/day for 7 days, followed by an intramuscular injection of 1 dose of Diphereline 3 75mg on day 8, and then every 4 weeks.
- Intramuscular injection of 1 dose of Diphereline 3 75mg from the start, administered every 4 weeks.
Dosage for Precocious Puberty Treatment:
- Children under 20kg: Intramuscular injection of ½ vial of Diphereline 3 75mg every 4 weeks (38 days), administering approximately half of the prepared solution.
- Children weighing 20-30kg: Intramuscular injection of ⅔ vial of Diphereline 3 75mg every 4 weeks, administering about ⅔ of the prepared solution.
- Children over 30kg: Intramuscular injection of 1 vial of Diphereline 3 75mg every 4 weeks, administering the full amount of the prepared solution.
Dosage for Endometriosis Treatment:
Patients will receive an intramuscular injection of 1 vial of Diphereline 3 75mg every 4 weeks. The first dose should be administered during the first 5 days of the menstrual cycle. The duration of treatment for endometriosis with Diphereline 3 75mg will depend on the initial severity of the disease and the clinical changes observed during treatment. Generally, endometriosis can be treated with Diphereline 3 75mg for at least 4 months and not more than 6 months. Diphereline 3 75mg should be used for one treatment cycle only.
Dosage for Female Infertility Treatment:
On day 2 of the menstrual cycle, the patient will receive an intramuscular injection of 1 vial of Diphereline 3 75mg. After about 15 days of Diphereline 3.75mg administration, the drug may be used in combination with gonadotropins when the pituitary gland has been suppressed and the estrogen level in the blood is below 50pg/ml.
Dosage for Pre-Surgical Treatment of Uterine Fibroids:
The patient will receive an intramuscular injection of 1 vial of Diphereline 3.75mg every 4 weeks, with the first dose administered during the first 5 days of the menstrual cycle. The pre-surgical treatment for uterine fibroids with Diphereline 3.75mg should not exceed 3 months.
3.2. Usage Instructions for Diphereline 3 75mg
Diphereline 3 75mg is administered via injection and is used for children over 5 years old and adults. Before administering Diphereline 3 75mg, patients must follow all instructions provided by their doctor to ensure the medication is used safely and effectively.
4. The side effects of Diphereline 3 75mg
Diphereline 3 75mg may cause the following side effects during treatment:
- Very common reactions: Hot flashes, tingling sensation in the lower limbs, increased sweating, fatigue, back pain.
- Common reactions: Headache, dizziness, depression, muscle and joint pain, nausea, fatigue, or decreased libido.
- Uncommon reactions: Gout, loss of appetite, numbness, insomnia, shortness of breath, hypertension, tinnitus, constipation, abdominal pain, vomiting, diarrhea, rash or itching.
- Rare reactions: Purpura, pharyngitis, diabetes, memory impairment, confusion, anaphylactic reactions, dizziness, bloating, or nosebleeds.
Patients should immediately inform their doctor if they experience one or any of the above-mentioned side effects while using Diphereline 3 75mg.
5. Precautions when using Diphereline 3 75mg
5.1. What should be cautioned when treating with Diphereline 3 75mg?
Here are the precautions that patients need to be aware of and follow when using Diphereline 3 75mg:
- Treatment with Diphereline 3 75mg should be carefully considered for pediatric patients under 18 years of age and those with osteoporosis.
- While using Diphereline 3 75mg, patients should avoid consuming alcohol or abusing stimulants, as this may increase the risk of side effects.
- Patients should adhere to the dosage and duration prescribed by the treating physician.
- Do not inject Diphereline 3 75mg if the medication has expired, if the powder has changed color, appears moldy, or has any abnormalities like cloudiness or precipitation after reconstitution.
- If the medication has expired, patients should dispose of it according to the instructions provided by healthcare professionals.
- The Diphereline 3 75mg injection solution should be prepared just before administration.
- GnRH agonists like Diphereline 3 75mg can increase the risk of reduced bone density.
- Special caution is needed for patients with risk factors for osteoporosis, such as smoking, chronic alcohol use, family history of osteoporosis, malnutrition, or long-term use of medications that reduce bone density (e.g., corticosteroids or anticonvulsants).
- Diphereline 3 75mg should not be used in pregnant women.
- Triptorelin treatment may increase the risk of severe depression.
- Care should be taken when using Diphereline 3 75mg in patients who have been treated with anticoagulants, as it may lead to the accumulation of blood at the injection site.
5.2. Drug Interactions of Diphereline 3 75mg with Other Medications
Here are the types of medications that may interact when used together with Diphereline 3 75mg, including:
- Medications that affect the secretion of gonadotropins from the pituitary gland.
- Drugs that may prolong the QT interval.
- Drugs that cause torsades de pointes, such as Group IA (Disopyramide, Quinidine) and Group III (Dofetilide, Sotalol, Ibutilide, and Amiodarone).
- Antiarrhythmic medications.
- Moxifloxacin.
- Methadone.
- Antipsychotic drugs.
Diphereline 3 75mg belongs to the ETC category and is used to treat diseases such as prostate cancer, endometriosis stages I – IV, precocious puberty in both boys and girls, female infertility, or for preoperative treatment of uterine fibroids. Follow the Vinmec International General Hospital website to learn more about health, nutrition, and beauty to protect the health of yourself and your loved ones.
To arrange an appointment, please call HOTLINE or make your reservation directly HERE. You may also download the MyVinmec app to schedule appointments faster and manage your reservations more conveniently.
